Compare EGY & AGMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | EGY | AGMB |
|---|---|---|
| Founded | 1985 | 2017 |
| Country | United States | Belgium |
| Employees | N/A | 62 |
| Industry | Oil & Gas Production | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 569.3M | 562.4M |
| IPO Year | 1996 | N/A |
| Metric | EGY | AGMB |
|---|---|---|
| Price | $4.99 | $15.25 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.30 | ★ $32.00 |
| AVG Volume (30 Days) | ★ 1.4M | 106.8K |
| Earning Date | 05-07-2026 | 04-23-2026 |
| Dividend Yield | ★ 3.75% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $359,272,000.00 | N/A |
| Revenue This Year | $8.78 | N/A |
| Revenue Next Year | $29.81 | $17.86 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.36 | $8.75 |
| 52 Week High | $6.72 | $17.45 |
| Indicator | EGY | AGMB |
|---|---|---|
| Relative Strength Index (RSI) | 34.49 | 81.73 |
| Support Level | $4.55 | $9.54 |
| Resistance Level | $5.69 | N/A |
| Average True Range (ATR) | 0.20 | 1.34 |
| MACD | -0.04 | 0.67 |
| Stochastic Oscillator | 21.24 | 100.00 |
VAALCO Energy Inc is an independent energy company engaged in the acquisition, exploration, development, and production of crude oil, natural gas, and natural gas liquids (NGLs). It has a diversified, African-focused portfolio of production, development, and exploration assets located in Gabon, Egypt, Cote d'Ivoire, Equatorial Guinea, and Nigeria, which are also considered its reportable operating segments. Maximum revenue is generated from the Gabon segment, which holds working interest in and operates the Etame Marin block, located offshore Gabon. The company derives all of its revenue from crude oil, natural gas, and natural gas liquids sales.
AgomAb Therapeutics NV is a clinical-stage biopharmaceutical company focused on developing novel disease-modifying therapies for immunology and inflammatory diseases, with an initial focus on chronic fibrotic indications with high unmet medical need. Its product candidates are designed to target established pathways and utilize validated modalities, with a focus on addressing limitations associated with prior treatment approaches. The company's pipeline includes small molecule and antibody product candidates aimed at targets associated with fibrotic diseases. Key candidates include Ontunisertib (AGMB-129) and AGMB-447.